Cybin Inc. announced the appointment of Aaron Bartlone as Chief Operating Officer of the company, effective July 1, 2023. Mr. Bartlone has served as Chief Operating Officer of Cybin’s U.S. subsidiary, Cybin US Holdings Inc., since March 2021. With 30 years of experience in the biopharmaceutical industry, Mr. Bartlone has a track record of driving novel therapeutics through clinical development into global markets, with significant expertise in the areas of product development, commercial operations, quality assurance and regulatory affairs.

Previously, Mr. Bartlone held roles of increasing responsibility, including Commercial President and Chief Quality, Patient Safety, Health Safety & Environment & Risk Officer at UCB Inc. Mr. Bartlone has successfully driven over 25 small and large molecular therapies and drug-device combination products to the global marketplace and has developed global teams of over 1,000 colleagues in 50 countries. Mr. Bartlone has also held various director-level product development, quality, regulatory, and managerial positions at Eli Lilly. Mr. Bartlone has a Bachelor of Science in Chemistry from Youngstown State University and a Master of Science in Analytical Chemistry from the University of Notre Dame.